Breaking News, Collaborations & Alliances

Lupin, Salix Expand Rifaximin Pact

Lupin Ltd. has granted Salix Pharmaceuticals, Ltd. exclusive worldwide rights (except for India) to use Lupin technology for all rifaximin products for human use.

Lupin Ltd. has granted Salix Pharmaceuticals, Ltd. exclusive worldwide rights (except for India) to use Lupin technology for all rifaximin products for human use. This agreement expands the companies’ collaboration dating back to September 2009. Under the expanded agreement Lupin will supply Salix with rifaximin API and certain finished rifaximin products.

Lupin will receive a $10 million up-front payment as well as potential U.S. regulatory milestones for products covered by Lupin patents or jointly held patents. Lupin is also eligible to receive royalties on sales. Additionally, Salix will pay Lupin minimum quarterly payments for product development and other activities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters